Don't Rely on Anti-Xa Levels to Verify LMWH Efficacy or Safety
July 2016
We're getting questions about how to dose low-molecular-weight heparin (LMWH) for venous thromboembolism in obesity and renal impairment.
Dosing a LMWH (enoxaparin, etc) can be tricky in these cases. Usual doses may not be enough for obese patients...or they may accumulate and be too much for patients with renal impairment.
Obesity. For acute venous thromboembolism (VTE) treatment, dose LMWH based on ACTUAL body weight...even in patients over 150 kg.
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote